Formulation Research & Development
Transforming Pharmaceutical Science into Better Therapeutic Solutions
At Zeeviezee Bio Pharma, formulation research and development is driven by one fundamental purpose: to transform pharmaceutical science into safe, effective, stable, scalable and patient-centric drug products that address real healthcare needs.
Our formulation R&D capabilities bring together drug substance/API expertise, formulation science, analytical development, process development, intellectual property and regulatory understanding to develop pharmaceutical products from concept to commercialization.
With capabilities spanning Formulation R&D, API R&D, CDMO and CRAMS, Zeeviezee Bio Pharma works across the pharmaceutical development lifecycle to create differentiated products and development solutions for domestic and international markets.
Our innovation-led approach is supported by an expanding portfolio of intellectual property and international patent opportunities, including innovations intended for global markets. Our development philosophy is aligned with internationally recognized pharmaceutical development and quality principles, including ICH Quality by Design (QbD), Quality Risk Management and pharmaceutical quality-system concepts.
Our Purpose
Developing Medicines with Purpose, Precision and Impact
The purpose of formulation R&D is not simply to combine an API with excipients. It is to understand how the drug substance, formulation composition, manufacturing process, dosage form and patient requirements interact to create a consistent and clinically useful pharmaceutical product.
At Zeeviezee Bio Pharma, our purpose is to:
- Develop innovative and differentiated pharmaceutical formulations
- Improve drug performance, stability, bioavailability and patient usability
- Address challenges associated with poorly soluble, unstable or difficult-to-formulate APIs
- Develop patient-centric dosage forms and drug-delivery approaches
- Convert scientific concepts into commercially viable pharmaceutical products
- Support development for regulated and emerging international markets
- Generate and protect intellectual property through differentiated pharmaceutical technologies
- Enable efficient transition from laboratory development to scalable manufacturing
- Support partners through CDMO and CRAMS development models
- Contribute to the availability of quality medicines that can improve healthcare outcomes
Our ultimate objective is to make pharmaceutical innovation meaningful to patients and healthcare systems.
Why Formulation R&D Is Essential
A promising API does not automatically become a successful medicine.
The final drug product must deliver the active pharmaceutical ingredient in a consistent, safe, stable and therapeutically appropriate manner. Formulation development therefore plays a critical role in converting an API into a usable dosage form.
Formulation R&D helps address challenges such as:
Poor Solubility
Many drug molecules have limited aqueous solubility, which can affect dissolution and ultimately drug exposure. Formulation science can explore appropriate technologies and excipient systems to improve performance.
Poor Bioavailability
A drug may demonstrate promising pharmacological activity while exhibiting inadequate bioavailability. Formulation strategies can be investigated to improve absorption and therapeutic performance.
Stability Challenges
Chemical and physical instability can affect product quality and shelf life. Formulation development evaluates appropriate excipients, manufacturing conditions, packaging and storage conditions to improve product stability
.Patient Compliance
The effectiveness of a medicine also depends on whether patients can use it conveniently. Appropriate dosage forms, strengths, administration routes and drug-delivery technologies can improve usability and adherence.
Manufacturing Complexity
A formulation must not only work in the laboratory; it must be capable of being manufactured consistently. Process understanding and scale-up are therefore integral components of formulation development.
Global Regulatory Requirements
Pharmaceutical products intended for international markets must be developed with appropriate quality, safety, performance and documentation considerations. ICH Q8 emphasizes scientific pharmaceutical development and understanding of the product and manufacturing process, while FDA’s current Q8/Q9/Q10 implementation guidance continues to support these principles.
Our Formulation R&D Approach
From Molecule to Market-Ready Product
At Zeeviezee Bio Pharma, formulation development follows a systematic, science-driven and risk-based approach.
1. Product Understanding
Development begins with understanding the molecule and defining the intended product characteristics.
We evaluate factors such as:
API physicochemical properties
Solubility
Particle characteristics
Hygroscopicity
Polymorphism
Melting characteristics
Chemical and physical stability
Drug-excipient compatibility
Dose requirements
Route of administration
Target patient population
Intended dosage form
Target market and regulatory requirements
This knowledge provides the foundation for rational formulation development.
2. Quality Target Product Profile
The development strategy is established around the intended product performance and quality requirements.
The Quality Target Product Profile (QTPP) helps define the desired characteristics of the final product and provides a foundation for identifying relevant Critical Quality Attributes (CQAs) and developing an appropriate control strategy.
3. Preformulation Studies
Pre-formulation is one of the most important stages in pharmaceutical development.
Our scientific evaluation may include:
API characterization
Solubility assessment
pKa and partitioning considerations
Particle-size evaluation
Solid-state characterization
Polymorph assessment
Hygroscopicity studies
Flow and compressibility evaluation
Thermal characterization
Drug-excipient compatibility studies
Forced degradation and stress evaluation
Preliminary stability assessment
The information generated during preformulation helps scientists select appropriate formulation strategies and reduce development risks.
4. Excipient Selection
Excipients are carefully evaluated based on their functional role, compatibility, safety and suitability for the intended dosage form.
Depending on the product, formulation scientists may evaluate:
Binders
Disintegrants
Lubricants
Fillers
Surfactants
Solubilizers
Suspending agents
Preservatives
Buffers
Antioxidants
Coating materials
Modified-release polymers
Functional excipients
The objective is to create an excipient system that supports product performance, manufacturability, stability and patient acceptability.-
Formulation Development
Our formulation development activities can encompass multiple dosage forms and pharmaceutical technologies, depending on project requirements.
Solid Oral Dosage Forms
Immediate-release tablets
Capsules
Modified-release formulations
Sustained-release formulations
Extended-release systems
Multiparticulate systems
Oral powders and granules
Liquid and Semi-Solid Formulations
Oral liquids
Suspensions
Solutions
Emulsions
Topical formulations
Creams
Gels
Ointments
Advanced Drug-Delivery Technologies
“Where scientifically appropriate, our R&D approach can explore differentiated drug-delivery technologies designed to address specific pharmaceutical challenges.”
These may include:
Solubility-enhancement approaches
Modified drug-release technologies
Novel drug-delivery systems
Patient-centric dosage forms
Combination-product concepts
Drug-device combination approaches
Other differentiated formulation technologies
Quality by Design — QbD
Our formulation development philosophy incorporates Quality by Design (QbD) principles wherever appropriate.
QbD focuses on building quality into the product and process through scientific understanding rather than relying solely on end-product testing.
The approach can involve:
QTPP → CQAs → Risk Assessment → Formulation Variables → Process Parameters → Design Space → Control Strategy
This enables development teams to understand the relationships between formulation components, process variables and product quality.
FDA and ICH guidance identify QTPP, CQAs, appropriate manufacturing processes and control strategies as important elements of pharmaceutical development.
Formulation Optimization
Once an initial formulation is established, systematic optimization is performed to identify a robust formulation and manufacturing process.
Depending on project requirements, studies may evaluate:
API concentration
Excipient concentrations
Binder levels
Disintegrant levels
Lubrication conditions
Granulation parameters
Compression parameters
Coating parameters
Mixing conditions
Processing time
Temperature
Moisture
Dissolution performance
Stability
Physical characteristics
Design of Experiments (DoE), statistical evaluation and risk-based development approaches can be used to understand interactions between formulation variables and process parameters.
Analytical & Performance Evaluation
Formulation development is closely integrated with analytical R&D.
Product performance may be evaluated through appropriate analytical and pharmaceutical tests, including:
Assay
Related substances
Dissolution
Content uniformity
Disintegration
Drug release profile
Particle-size analysis
Physical characterization
Moisture determination
Stability-indicating analysis
Microbiological evaluation where applicable
Analytical development provides the scientific evidence required to understand formulation performance and support development decisions.
Stability Studies
Stability is fundamental to pharmaceutical product development.
Our formulation development strategy considers stability from the early development stage and evaluates appropriate conditions to understand:
Chemical stability
Physical stability
Drug-excipient interactions
Degradation pathways
Dissolution changes
Appearance changes
Moisture-related effects
Packaging compatibility
Shelf-life considerations
Stability knowledge supports formulation selection, packaging decisions and product lifecycle development.
Scale-Up & Technology Transfer
A successful laboratory formulation must ultimately be capable of reproducible manufacturing.
Our development approach therefore considers scale-up from the early stages of formulation development.
Activities may include:
Laboratory Development → Pilot Development → Process Optimization → Scale-Up → Technology Transfer → Process Validation → Commercial Manufacturing
The objective is to maintain product quality and performance while transitioning from development scale to manufacturing scale.
ICH principles emphasize pharmaceutical development and process understanding as foundations for establishing manufacturing controls and maintaining product quality throughout the product lifecycle.
Formulation R&D Integrated with API R&D
One of the key strengths of Zeeviezee Bio Pharma is the ability to connect API R&D and formulation R&D.
This integrated approach enables scientists to consider the relationship between:
API → Physicochemical Properties → Formulation → Manufacturing Process → Analytical Method → Product Performance
API characteristics can significantly influence formulation behavior. By bringing drug-substance and drug-product development expertise together, development teams can investigate problems earlier and design more effective development strategies.
Our API R&D capabilities can support areas such as:
API process development
Impurity understanding
Solid-state considerations
Particle engineering
Route optimization
Process understanding
Scale-up support
This integrated scientific ecosystem can help accelerate the journey from molecule to finished dosage form.
Intellectual Property & Innovation
Innovation is at the heart of our formulation R&D philosophy.
At Zeeviezee Bio Pharma, formulation development is not limited to reproducing established pharmaceutical technologies. We actively explore opportunities to develop differentiated formulations, novel delivery approaches, improved product performance and commercially meaningful pharmaceutical technologies.
Our intellectual-property strategy supports the identification and protection of innovations arising from pharmaceutical research.
Our portfolio includes international intellectual property and patent-related innovations, including U.S.-focused IP, supporting our ambition to develop technologies with global relevance.
Important: Patent rights and regulatory approvals are separate matters. Patented technology does not itself constitute FDA approval. Our development activities are designed to support appropriate regulatory pathways and internationally applicable quality expectations.
CDMO & CRAMS Formulation Development
Zeeviezee Bio Pharma extends its formulation R&D capabilities to CDMO and CRAMS partnerships, supporting pharmaceutical companies, biotechnology organizations and research-driven enterprises.
Our development partnership model can support:
Formulation feasibility studies
Preformulation
Formulation development
Prototype development
Analytical support
Process development
Scale-up
Technology transfer
Stability programs
Development documentation
Clinical-development support
Manufacturing support
Our objective is to provide partners with an integrated development pathway while maintaining scientific rigor, confidentiality and intellectual-property considerations.
Our Development Philosophy
Science First
Every formulation decision should have a scientific rationale.
Patient Centricity
The final product should be designed with patient needs, usability and therapeutic performance in mind.
Quality by Design
Quality should be built into the formulation and manufacturing process from the beginning.
Innovation
We continuously explore opportunities for differentiated pharmaceutical technologies and intellectual property.
Regulatory Readiness
Development should generate appropriate scientific knowledge and documentation to support the intended regulatory pathway.
Scalability
A formulation should be designed with commercial manufacturing considerations in mind.
Lifecycle Thinking
Product and process understanding should continue from development through manufacturing and lifecycle management. FDA/ICH quality guidance emphasizes maintaining and expanding product and process knowledge throughout the lifecycle.
Benefits to Mankind
From Pharmaceutical Innovation to Human Impact
The ultimate purpose of formulation R&D is not the formulation itself.
It is the patient.
Every improvement in pharmaceutical formulation has the potential to make treatment more accessible, effective, convenient or reliable.
Innovative formulation research can contribute to:
Better drug delivery
Improved patient convenience
Improved medication adherence
Enhanced product stability
Better therapeutic performance
More convenient dosage forms
Potentially improved bioavailability
Improved manufacturing efficiency
Longer and more reliable product shelf life
Development of medicines for unmet healthcare needs
Broader access to quality pharmaceutical products
By combining API science, formulation expertise, analytical R&D, process development, intellectual property and manufacturing capabilities, Zeeviezee Bio Pharma seeks to bridge the gap between scientific discovery and meaningful healthcare solutions.
From Research to Real-World Healthcare
At Zeeviezee Bio Pharma, we believe pharmaceutical innovation should create measurable value beyond the laboratory.
Our integrated capabilities across:
API R&D | Formulation R&D | Analytical R&D | CDMO | CRAMS | Intellectual Property | Scale-Up | Manufacturing
enable us to approach pharmaceutical development as a connected scientific journey.
Why Partner with Zeeviezee Bio Pharma?
Integrated R&D Ecosystem
API, formulation and analytical development capabilities working together.
Innovation & Intellectual Property
A strong focus on differentiated technologies and intellectual-property creation.
Global Development Perspective
Development approaches designed with international markets and regulatory expectations in mind.
CDMO & CRAMS Capability
Flexible development and outsourcing models for pharmaceutical and biotechnology partners.
Science-Driven Development
QbD, risk-based development and systematic pharmaceutical development principles.
From Concept to Commercialization
Supporting the development journey from early scientific concept through scale-up and manufacturing.
AI-Integrated Formulation R&D
Accelerating Pharmaceutical Innovation Through Science and Artificial Intelligence
At Zeeviezee Bio Pharma, we are exploring the integration of Artificial Intelligence (AI), data science and advanced computational approaches into formulation research and development to make pharmaceutical development more informed, efficient and predictive.
By connecting AI-enabled approaches with our capabilities in API R&D, formulation R&D, analytical development, CDMO and CRAMS, we aim to enhance decision-making across the pharmaceutical development lifecycle.
AI can support formulation scientists in analyzing complex datasets, identifying relationships between API properties, excipients, formulation variables and process parameters, predicting formulation behavior, prioritizing experimental conditions and accelerating optimization.